They act on unrelated systems and were measured against unrelated endpoints. Semaglutide is a GLP-1 receptor agonist studied on blood glucose, cardiovascular events, kidney outcomes, and body weight in large randomized trials. The marketed research peptides act mostly on tissue repair or growth hormone release, and their published results come from animals, cells, or small exploratory work.
What semaglutide does, mechanically
GLP-1 receptor agonism produces a set of effects that have been described in detail: glucose-dependent insulin secretion, suppressed glucagon release, slowed gastric emptying, and reduced appetite signals in the central nervous system. A 2024 review of GLP-1 and dual GIP/GLP-1 receptor agonist pharmacology covers how these overlap and where the dual agonists differ. The mechanism was not inferred backward from weight results. It was characterized first, then tested against endpoints chosen in advance.
Those endpoints matter for reading any result. Ozempic’s approved indications, checked on DailyMed, are glycemic control in adults with type 2 diabetes, reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and reduction of the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. The weight endpoints belong to Wegovy, the semaglutide product approved for chronic weight management, whose principal trial randomized adults with overweight or obesity and no diabetes for 68 weeks and reported mean weight change of about 14.9 percent against about 2.4 percent for placebo.
See also: What Is Double Spending Problem?
What the marketed peptides do, mechanically
The compounds people group under peptides in this query do not share a mechanism with each other, let alone with semaglutide.
BPC-157 is a pentadecapeptide derived from a gastric protein, studied mainly in rodent models of tendon, ligament, muscle, and gut injury, with proposed effects on angiogenesis and healing signals. A 2026 review of it as an investigational therapeutic sets out the formulation, stability, and translational obstacles that have kept it from becoming an approved product. Ipamorelin and CJC-1295 act upstream of growth hormone release, one as a secretagogue and one on the releasing hormone side, an area covered in a 2026 review of performance-enhancing peptides acting on the GH-IGF1 axis. AOD-9604 is a fragment of the growth hormone molecule, with published work including an intra-articular injection study in a rabbit osteoarthritis model. MOTs-C is a mitochondria-derived peptide studied for effects on muscle bioenergetics through PGC-1 alpha and AMPK signaling. And 5-Amino-1MQ is not a peptide at all, but a small-molecule inhibitor of nicotinamide N-methyltransferase, whose obesity-relevant published work has been done in diet-induced obese mice.
Appetite regulation is not the target of any of them. Weight change is not the endpoint any of them was measured on.
| Compound | Primary mechanism as studied | Endpoint the published work measured | Evidence class |
|---|---|---|---|
| Semaglutide (Ozempic) | GLP-1 receptor agonism | HbA1c, cardiovascular events, kidney outcomes | Large randomized and outcome trials |
| Semaglutide (Wegovy) | GLP-1 receptor agonism | Body weight, cardiovascular events, liver histology in MASH | Large randomized trials |
| Compounded semaglutide | Same receptor target | None for the preparation itself | Adverse event reporting only |
| BPC-157 | Tissue repair and angiogenesis signaling | Healing in rodent injury models | Animal and laboratory; older exploratory human work |
| Ipamorelin, CJC-1295 | Growth hormone release | Hormone levels, not clinical outcomes | Pharmacology studies and narrative reviews |
| AOD-9604 | Growth hormone fragment | Joint tissue in a rabbit model | Animal |
| MOTs-C | Mitochondrial signaling via AMPK | Muscle bioenergetics, serum levels in patient groups | Animal and observational biomarker |
| 5-Amino-1MQ | NNMT enzyme inhibition, small molecule | Body composition and microbiome in obese mice | Animal |
Why the evidence classes cannot be averaged together
A rodent healing model and a 68-week randomized trial with a pre-specified endpoint are not two grades of the same thing. The trial answers what happened to people assigned to the drug compared with people assigned to placebo. The animal study answers what happened in an animal, under conditions designed to make an effect visible. Reviews of injectable peptide use in sports and orthopedic settings have made this gap explicit, describing marketing claims that outrun the data by a wide margin.
FDA’s own position adds a second layer. Its page on bulk drug substances that may present significant safety risks describes immunogenicity and characterization concerns for several of these compounds, notes serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction, and states that the agency has identified no human exposure data for MOTs-C by any route of administration. That is not a verdict about efficacy. It is a statement that the basic human information is missing.
Since supervision does not turn an animal finding into a human one, the provider a person picks changes the price and the monitoring, never the strength of the underlying data. That is the useful lens for reading how each service lists the approved drug: Ro, Henry Meds, and LifeMD post monthly cash rates, the manufacturer channels at LillyDirect and NovoCare Pharmacy quote branded pricing, and a provider such as HealthRX publishes an Ozempic page describing who qualifies and what oversight comes with it. None of that moves a research peptide out of the evidence class its studies sit in.
Expected results, stated honestly
For approved semaglutide products, group averages exist and are large, though individual results in those cohorts spread widely and real-world adherence is lower than trial adherence. A separate randomized trial of tirzepatide over 72 weeks reported larger mean reductions, but placing those two numbers side by side is a cross-trial comparison between studies with different populations and different placebo responses, not a head-to-head result.
For the research peptides, no expected result can be stated, because no study has produced one in humans for these uses. That is the honest answer, and it is worth more than a hedged estimate. Cost is what pushes most people to look, and comparing supervised routes on price and follow-up is sensible, whether that means Ro, Hims and Hers, LifeMD, a manufacturer channel, or checking the provider behind it before signing up. What changes with any of those choices is oversight and price, not the evidence attached to the molecule.
Frequently asked questions
Do any of these peptides affect appetite the way semaglutide does?
Not by the same route. GLP-1 receptor agonism acts on glucose-dependent insulin release, gastric emptying, and central appetite signals. The growth hormone axis compounds and repair peptides act elsewhere entirely, and appetite has not been the measured endpoint in the published work on them.
Is animal evidence worthless?
No, it is early. Animal models generate hypotheses and guide dose-finding before human testing begins. The problem is not the studies themselves but the leap from a rodent healing model to a marketed human product, which skips every step designed to catch a mechanism that fails to translate.
Why is 5-Amino-1MQ sold alongside peptides if it is not one?
Marketing grouping rather than chemistry. It is a small-molecule enzyme inhibitor rather than a peptide, and its metabolic literature is animal work. Being sold in the same category creates an impression of shared evidence that the underlying research does not support.
Does a stronger mechanism story predict a stronger result?
Rarely. Plausible mechanisms fail in trials often enough that regulators require outcome data regardless of how coherent the biology looks. A mechanism explains why a drug might work; only a trial establishes whether it did.
